{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:51:17Z","timestamp":1777866677817,"version":"3.51.4"},"reference-count":86,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Biological therapy is widely used to treat moderate-to-severe psoriasis. This study aimed to assess the real-world effectiveness and drug survival of biologic treatment in patients with moderate-to-severe psoriasis. Materials and Methods: A retrospective study of 210 patients with moderate-to-severe psoriasis who were treated with biological therapy between 2018 and 2023 was conducted. Baseline data included demographics, comorbidities, prior treatments, Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores, laboratory results, current psoriasis treatment, and treatment-related adverse events. Results: Of the 210 patients, 60.0% were male (n = 126). The mean age was 48.3 \u00b1 13.6 years in men (range 16\u201374) and 48.4 \u00b1 13.6 years in women (range 17\u201379). The mean PASI at initiation of biologic therapy was 15.0 \u00b1 8.1 and decreased to 3.3 \u00b1 4.7 at 1 year, 2.7 \u00b1 4.0 at 3 years, and 2.8 \u00b1 3.3 at 5 years. Drug discontinuation differed between therapies: etanercept had a higher hazard of discontinuation than ustekinumab (hazard ratio (HR) 2.55, 95% confidence interval (CI) 1.17\u20135.52; p = 0.0179), infliximab (HR 0.36, 95% CI 0.13\u20130.97; p = 0.0429) and adalimumab (HR 0.47, 95% CI 0.23\u20130.98; p = 0.0453). Conclusions: In routine clinical practice, biologic therapy was associated with substantial and sustained improvements in the PASI over up to 5 years of follow-up. Drug survival was initially high for all agents but separated over time, with etanercept showing the poorest long-term persistence and a higher hazard of discontinuation compared with other drugs.<\/jats:p>","DOI":"10.3390\/medicina62050855","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:46:26Z","timestamp":1777538786000},"page":"855","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania"],"prefix":"10.3390","volume":"62","author":[{"given":"Elada","family":"Indrisiunaite","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5541-5089","authenticated-orcid":false,"given":"Ieva Renata","family":"Jonaityte","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Disease and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Karmaziene","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Disease and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8852-1846","authenticated-orcid":false,"given":"Tadas","family":"Raudonis","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Disease and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. \u010ciurlionio g. 21, 03101 Vilnius, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.12688\/f1000research.19144.1","article-title":"Psoriatic arthritis","volume":"8","author":"Ocampo","year":"2019","journal-title":"F1000Research"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1111\/bjd.15610","article-title":"The global state of psoriasis disease epidemiology: A workshop report","volume":"177","author":"Griffiths","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: A review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_5","first-page":"158","article-title":"Immunopathogenic treatment options for psoriasis patients under a restrictive reimbursement environment","volume":"75","author":"Hartmane","year":"2021","journal-title":"Proc. Latv. Acad. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","article-title":"The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis","volume":"210","author":"Schmitt","year":"2005","journal-title":"Dermatology"},{"key":"ref_7","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014A simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2340\/00015555-3331","article-title":"Patient-reported outcomes during biologic treatment: A Danish nationwide study","volume":"99","author":"Loft","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_11","first-page":"CD005028","article-title":"Topical treatments for chronic plaque psoriasis","volume":"3","author":"Mason","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e12946","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis\u2014Head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Petrovic","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.det.2018.07.004","article-title":"Biologics and psoriasis: The beat goes on","volume":"37","author":"Kim","year":"2019","journal-title":"Dermatol. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjd.19018","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u2265 6 to <12 years of age): Efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study","volume":"183","author":"Philipp","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e15166","DOI":"10.1111\/dth.15166","article-title":"Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study","volume":"35","author":"Colombo","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"adv00712","DOI":"10.2340\/actadv.v102.206","article-title":"Direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative psoriasis area and severity index scores in a prospective multicentre cohort","volume":"102","author":"Thomas","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/dth.12267","article-title":"An evolution in switching therapy for psoriasis patients who fail to meet treatment goals","volume":"28","author":"Kerdel","year":"2015","journal-title":"Dermatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000345715","article-title":"Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice","volume":"225","author":"Norlin","year":"2012","journal-title":"Dermatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/jdv.13222","article-title":"Use of biologics for psoriasis in Central and Eastern European countries","volume":"29","author":"Rencz","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Eisen, M., Hartmane, I., Kingo, K., Mikazans, I., Toomson, T., Toomela, K., and Valiukeviciene, S. (2025). The Real-World Burden of Moderate-to-Severe Psoriasis in Patients Under Systemic Treatment from Baltic Countries: Data from the CRYSTAL Observational Study. Medicina, 61.","DOI":"10.3390\/medicina61030397"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","article-title":"Choosing first-line biologic treatment for moderate-to-severe psoriasis: What does the evidence say?","volume":"19","author":"Amin","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.jid.2021.02.743","article-title":"New frontiers in psoriatic disease research, part II: Comorbidities and targeted therapies","volume":"141","author":"Yan","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdv.16558","article-title":"Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)","volume":"35","author":"Bagel","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: Results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Express study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","article-title":"Predictors of response to biologics in patients with moderate-to-severe psoriasis: A Danish nationwide cohort study","volume":"101","author":"Schwarz","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: Defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"adv00357","DOI":"10.2340\/00015555-3722","article-title":"Response to biologics during the first six months of therapy in biologic-na\u00efve patients with psoriasis predicts risk of disease flares: A Danish nationwide study","volume":"101","author":"Loft","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_37","unstructured":"(2026, January 25). V-1014 D\u0117l Psoriaz\u0117s Gydymo Vaistais, Kuri\u0173 \u012esigijimo I\u0161laidos Apmokamos Privalomojo Sveikatos Draudimo Fondo Biud\u017eeto L\u0117\u0161omis, Tvarkos Apra\u0161o Patvirtinimo. Available online: https:\/\/www.e-tar.lt\/portal\/lt\/legalAct\/c51f3b408d8311e7a3c4a5eb10f04386\/asr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/jdv.14007","article-title":"Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: A systematic review and meta-analysis","volume":"31","author":"Puig","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/09546634.2016.1278198","article-title":"The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients","volume":"28","author":"Abrouk","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/1346-8138.15721","article-title":"Psychological burden of psoriatic patients in a German university hospital dermatology department","volume":"48","author":"Sondermann","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2015.12.017","article-title":"Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])","volume":"74","author":"Strober","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: A prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","article-title":"Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology","volume":"69","author":"Mohan","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2004.11.006","article-title":"The benefit\/risk profile of TNF-blocking agents: Findings of a consensus panel","volume":"34","author":"Hochberg","year":"2005","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1474-4422(06)70552-X","article-title":"Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: A descriptive study","volume":"5","author":"Barcellos","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Crisafulli, S., Bertino, L., Fontana, A., Calapai, F., Ingrasciotta, Y., Berretta, M., Trifir\u00f2, G., and Guarneri, C. (2021). Incidence of skin cancer in patients with chronic inflammatory cutaneous diseases on targeted therapies: A systematic review and meta-analysis of observational studies. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.687432"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jdv.16073","article-title":"Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: A systematic review and meta-analysis of phase III studies","volume":"34","author":"Loft","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/1060028017743268","article-title":"Treating moderate-to-severe plaque psoriasis with guselkumab: A review of phase II and phase III trials","volume":"52","author":"Howell","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_56","first-page":"317","article-title":"The efficacy of ustekinumab in psoriasis","volume":"12","author":"Famenini","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: A retrospective multi-country, multicentric cohort study","volume":"22","author":"Torres","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e14808","DOI":"10.1111\/dth.14808","article-title":"Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry","volume":"34","author":"Lockshin","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/bjd.19701","article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: A time-period-adjusted registry analysis","volume":"184","author":"Graier","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000504839","article-title":"Switching biologics in the treatment of psoriasis: A multicenter experience","volume":"237","author":"Aytekin","year":"2021","journal-title":"Dermatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/09546634.2019.1698699","article-title":"Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status","volume":"32","author":"Feldman","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40261-017-0603-3","article-title":"A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis","volume":"38","author":"Hu","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/jdv.18409","article-title":"Switches between biologics in patients with moderate-to-severe psoriasis: Results from the French cohort PSOBIOTEQ","volume":"36","author":"Curmin","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s13555-022-00834-7","article-title":"Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the CorEvitas Psoriasis Registry","volume":"12","author":"Lockshin","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/HJH.0b013e32835bcce1","article-title":"The association between psoriasis and hypertension: A systematic review and meta-analysis of observational studies","volume":"31","author":"Armstrong","year":"2013","journal-title":"J. Hypertens."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2133.2008.08707.x","article-title":"Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis","volume":"159","author":"Kaye","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamadermatol.2014.2094","article-title":"Effect of psoriasis severity on hypertension control: A population-based study in the United Kingdom","volume":"151","author":"Takeshita","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/archderm.141.12.1527","article-title":"Impact of obesity and smoking on psoriasis presentation and management","volume":"141","author":"Herron","year":"2005","journal-title":"Arch. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaad.2005.11.1079","article-title":"Psoriasis is associated with lipid abnormalities at the onset of skin disease","volume":"54","author":"Mallbris","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/09546634.2016.1254145","article-title":"The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: A retrospective study","volume":"29","author":"Shaaban","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/bjd.12101","article-title":"The association between psoriasis and dyslipidaemia: A systematic review","volume":"168","author":"Ma","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-2330","article-title":"Psoriasis and new-onset diabetes: A Danish nationwide cohort study","volume":"36","author":"Khalid","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jid.2017.07.841","article-title":"Objective measures of psoriasis severity predict mortality: A prospective population-based cohort study","volume":"138","author":"Noe","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jid.2020.11.025","article-title":"Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through trans-disease meta-analysis","volume":"141","author":"Patrick","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/archdermatol.2012.1401","article-title":"Increased risk of diabetes and likelihood of receiving diabetes treatment in patients with psoriasis","volume":"148","author":"Azfar","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jaad.2015.02.1095","article-title":"Psoriasis and risk of diabetes-associated microvascular and macrovascular complications","volume":"72","author":"Armstrong","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/archinte.167.15.1670","article-title":"Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses\u2019 Health Study II","volume":"167","author":"Setty","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2340\/00015555-3098","article-title":"Nail psoriasis: An updated review and expert opinion on available treatments, including biologics","volume":"99","author":"Bardazzi","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2021.09.019","article-title":"Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity","volume":"86","author":"Merola","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2147\/CCID.S417679","article-title":"Nail psoriasis: An updated review of currently available systemic treatments","volume":"16","author":"Battista","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"adv00324","DOI":"10.2340\/00015555-3682","article-title":"Incidence of psoriatic arthritis in patients with skin psoriasis and associated risk factors: A retrospective population-based cohort study in Swedish routine clinical care","volume":"100","author":"Lindberg","year":"2020","journal-title":"Acta Derm. Venereol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/855\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:08:55Z","timestamp":1777540135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":86,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["medicina62050855"],"URL":"https:\/\/doi.org\/10.3390\/medicina62050855","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}